Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MK-1308 |
| Trade Name | |
| Synonyms | MK1308|MK 1308|Quavonlimab |
| Drug Descriptions |
MK-1308 is a monoclonal antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response and decreased tumor growth (NCI Drug Dictionary). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | NA |
| NCIT ID | C150679 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Lenvatinib + MK-1308 + Pembrolizumab | Lenvatinib MK-1308 Pembrolizumab | 0 | 1 |
| MK-1308 | MK-1308 | 0 | 1 |
| MK-1308 + Pembrolizumab | MK-1308 Pembrolizumab | 0 | 2 |
| MK-1308 + Pembrolizumab + Vibostolimab | MK-1308 Pembrolizumab Vibostolimab | 0 | 1 |